Oct 03 2025 This Week in Cardiology
This Week in Cardiology
Medscape Podcasts
4.9 • 963 Ratings
🗓️ 3 October 2025
⏱️ 27 minutes
🧾️ Download transcript
Summary
Two great stories of translation science leading to beneficial drugs in terrible diseases of the heart and the Sisyphean task of predicting the need for pacing after TAVI are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Sotatercept
- HYPERION Trial https://www.nejm.org/doi/10.1056/NEJMoa2508170
- ZENITH Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160
- Evidence report on treatment for PAH https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-on-treatment-for-pulmonary-arterial-hypertension/
- PAH Sotatercept Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2503944
II Acoramidis and ATTR Cardiomyopathy
- ATTRIBUTE-CM Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2305434?logout=true
- ATTRIBUTE-CM Analysis - Substudy https://www.jacc.org/doi/10.1016/j.jacc.2025.09.013
- Tafamadis Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1805689
III Pacing After TAVI
- Prophylactic pacemaker after TAVI https://www.jacc.org/doi/10.1016/j.jacep.2025.07.028
- PROMOTE study https://doi.org/10.1016/j.hrthm.2024.12.019
- Evaluation of ESC criteria on RBBB patients undergoing TAVI https://doi.org/10.1016/j.hrthm.2024.11.030
- Editorial on Heart Rhythm journal papers https://www.heartrhythmjournal.com/article/S1547-5271(25)00114-6/abstract
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Transcript
Click on a timestamp to play from that location
| 0:00.0 | You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology. |
| 0:05.7 | This podcast is intended for health care professionals only. |
| 0:08.8 | Any views expressed are the presenters' own and do not necessarily reflect the views of WebMD or Medscape. |
| 0:14.6 | Hi, everyone. |
| 0:16.1 | This is John Mandrola from the heart.org medscape cardiology, and this is this week in cardiology for October 3rd, 2025. |
| 0:25.1 | This week, two great stories of translational science leading to beneficial drugs in terrible diseases of the heart, |
| 0:33.6 | and the Sisyphian task of predicting the need for permanent pacing after Tavi. |
| 0:39.5 | The lessons transcend just a simple EP question of pacing. |
| 0:44.2 | Okay, the first topic today is a new drug, a new drug that I don't think I've talked about on this podcast called a soda tersept. |
| 0:52.5 | Now, it's for pulmonary artery hypertension, |
| 0:55.1 | and I don't take care of patients with PAHH, |
| 0:57.4 | and perhaps you don't either. |
| 0:58.7 | But I want to spend a few moments |
| 1:01.0 | talking about this amazing story of translational science |
| 1:04.9 | and a breakthrough treatment for a disease |
| 1:07.3 | that is progressive and terrible, |
| 1:08.9 | and that is primary pulmonary artery hypertension. |
| 1:12.2 | Here's a brief background statement on PAH that I took from an editorial from Dr. Bradley Moran |
| 1:18.3 | in New England Journal of Medicine this May. |
| 1:21.6 | Pulmonary artery hypertension is an uncommon disorder. |
| 1:24.7 | It's characterized by pathologic remodeling of distal pulmonary arterials |
| 1:28.9 | and these changes increase PVR, pulmonary vascular resistance, which leads to a clinical |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.